Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20118725 | 0.87 | MEN1 (0.44) | MEN1KMT2ACREBBPEP300KDM4C | |
| SCHEMBL29273103 | 0.84 | MEN1 (0.39) | MEN1KMT2ACREBBPEP300KDM4C | |
| SCHEMBL1691135 | 0.84 | MEN1 (0.39) | MEN1KMT2ACREBBPEP300KDM4C | |
| SCHEMBL13391654 | 0.83 | MEN1 (0.39) | MEN1KMT2AKDM4CICAM1SELE | |
| SCHEMBL1691068 | 0.80 | MEN1 (0.37) | MEN1KMT2AALDH1A1 | |
| SCHEMBL16775499 | 0.80 | MEN1 (0.41) | MEN1KMT2ACREBBPEP300KDM4C | |
| SCHEMBL11634891 | 0.79 | MEN1 (0.38) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL22468403 | 0.79 | MEN1 (0.38) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL22488305 | 0.79 | MEN1 (0.38) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL15457456 | 0.78 | MEN1 (0.37) | MEN1KMT2AKDM4CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE44768-E1 | Rapamycin hydroxyesters | WYETH LLC (US) | 2014-02-18 | — | — | US | claimed |
| EP-2279741-A2 | Caprolactams and their use as anti-inflammatory agents | Cambridge Enterprise Ltd. (GB) | 2011-02-02 | — | — | EP | claimed |
| US-20080227724-A1 | 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2008-09-18 | — | — | US | claimed |
| EP-1760083-A1 | Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them | Wyeth (US) | 2007-03-07 | — | — | EP | claimed |
| EP-1266899-B1 | Rapamycin hdroxyesters, process for their preparation and pharmaceutical compositions containing them | WYETH CORP (US) | 2007-01-03 | — | — | EP | claimed |
| EP-1691814-A2 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2006-08-23 | — | — | EP | claimed |
| WO-2005053702-A2 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2005-06-16 | — | — | WO | claimed |
| EP-1266899-A2 | Rapamycin hdroxyesters, process for their preparation and pharmaceutical compositions containing them | Wyeth (US) | 2002-12-18 | — | — | EP | claimed |
| EP-0763039-A1 | RAPAMYCIN HYDROXYESTERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-03-19 | — | — | EP | claimed |
| WO-1995028406-A1 | RAPAMYCIN HYDROXYESTERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-10-26 | — | — | WO | claimed |
| US-5362718-A | Rapamycin hydroxyesters | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-11-08 | — | — | US | claimed |
| US-RE44768-E1 | Rapamycin hydroxyesters | WYETH LLC (US) | 2014-02-18 | — | — | US | disclosed |
| EP-1691814-B9 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTPR LTD (GB) | 2013-02-20 | — | — | EP | disclosed |
| EP-1691814-B1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTPR LTD (GB) | 2012-07-25 | — | — | EP | disclosed |
| EP-2279741-A2 | Caprolactams and their use as anti-inflammatory agents | Cambridge Enterprise Ltd. (GB) | 2011-02-02 | — | — | EP | disclosed |
| EP-1266899-B1 | Rapamycin hdroxyesters, process for their preparation and pharmaceutical compositions containing them | WYETH CORP (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1691814-A2 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005053702-A2 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
| EP-1266899-A2 | Rapamycin hdroxyesters, process for their preparation and pharmaceutical compositions containing them | Wyeth (US) | 2002-12-18 | — | — | EP | disclosed |
| US-5362718-A | Rapamycin hydroxyesters | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227724-A1 | 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents | SMURF1, SMURF2, PSEN1 | MEN1 2473/4885KMT2A 3114/4885CREBBP 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.